Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Acute 10Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Leukemia 3Multiple Myeloma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hodgkin Disease 2Gliosarcoma 2Glioblastoma 2Warts 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pinealoma 1Neutropenia 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Medulloblastoma 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma 1Leukopenia 1Leukemia, Lymphocytic, Chronic, B-Cell 1Infections 1Immunologic Deficiency Syndromes 1Hematologic Neoplasms 1Graft vs Host Disease 1Glioma 1Brain Neoplasms 1Agammaglobulinemia 1Acquired Immunodeficiency Syndrome 1

Interventions

Temozolomide 10Irinotecan 8Cyclophosphamide 7dinutuximab 5aldesleukin 4Interleukin-2 4Granulocyte-Macrophage Colony-Stimulating Factor 4sargramostim 3fludarabine 3Topotecan 3Melphalan 3Isotretinoin 3Filgrastim 3gallium Ga 68 dotatate 2Vincristine 2TPI-287 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Magnetic Resonance Spectroscopy 2Carboplatin 2venetoclax 1trametinib 1thymoglobulin 1talazoparib 1sonidegib 1silmitasertib 1plerixafor 1olaparib 1naxitamab 1lutetium Lu 177 dotatate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neuroblastoma × plerixafor × Clear all
NCT01288573 2017-05-16

A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone

Sanofi

Phase 1/2 Completed
46 enrolled
CNS

Brain Neoplasms, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡